Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 9,900 shares, a growth of 54.7% from the May 31st total of 6,400 shares. Based on an average daily trading volume, of 32,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the company’s shares are sold short.
Analyst Ratings Changes
Separately, StockNews.com started coverage on Tenax Therapeutics in a report on Sunday. They set a “sell” rating on the stock.
Check Out Our Latest Analysis on TENX
Tenax Therapeutics Price Performance
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). Sell-side analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Most Volatile Stocks, What Investors Need to Know
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.